New drug combo for advanced esophageal cancer after immunotherapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two drugs (QL1706 and lenvatinib) for people whose esophageal cancer has progressed after initial immunotherapy. The goal is to see if this combination can help shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have esophageal cancer that is squamous cell type and cannot be removed by surgery or has spread to other parts of the body.
- Your cancer must have gotten worse while taking a PD-1 or PD-L1 inhibitor (a type of immunotherapy) as your first treatment.
- You must have at least one tumor that can be measured on a scan.
- You must be in generally good health, able to take care of yourself (performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new immunotherapy drug (QL1706) combined with an anti-inflammatory drug (celecoxib) for advanced esophageal cancer that has progressed after previous immunotherapy. It may help slow down tumor growth and give you more treatment options.
This trial tests a new combination of drugs (QL1706, nab-paclitaxel, and cisplatin) as a first treatment for advanced or metastatic esophageal squamous cell carcinoma. The goal is to see if this combination is safe and effective in shrinking tumors and helping patients live longer.
This study tests a new experimental drug that combines two ways to boost your immune system to fight cancer. It is for people with advanced esophageal cancer whose cancer didn't respond to previous immunotherapy and chemotherapy.
This trial tests a new drug (QL1706) combined with bevacizumab, with or without chemotherapy, for people with advanced non-squamous non-small cell lung cancer that has grown after prior immunotherapy. It aims to see if this combination can help control the cancer.
This trial tests a new immunotherapy drug, QL1706, given before surgery for esophageal squamous cell cancer. The goal is to see if it helps shrink tumors and improve outcomes for patients who are healthy enough for the treatment.
This trial tests a combination of three drugs (QL1706, lenvatinib, and chemotherapy) as the first treatment for people with advanced pancreatic cancer that has spread to other parts of the body. It aims to see if this combination is safe and effective.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.